English Polski

Advanced search

Vol 27, No 1 (2021)
Review papers
Published online: 2021-06-01

open access

View PDF Download PDF file
Page views 864
Article views/downloads 567
Get Citation

Connect on Social Media

Connect on Social Media

The role of selected metalloproteinases and some genetic factors in the pathogenesis of abdominal aortic aneurysm

Stanisław Surma1, Karolina Stolorz1, Oskar Sierka1, Aleksander Ludwik Sieroń1, Marta Lesiak1
DOI: 10.5603/AA.2021.0005
Acta Angiologica 2021;27(1):22-31.

Abstract

Aortic aneurysm is defined as a pathologically dilated segment of the main artery. There are three main types of aortic aneurysms: real, pseudo and dissecting. The most common aneurysms are abdominal aortic aneurysms defined as vasodilatation equal to or above 30 mm. Abdominal aortic aneurysm development is usually asymptomatic. Many various risk factors have been linked to AAA development. The pathophysiology of AAA is associated with inflammation, smooth muscle cells apoptosis and matrix degradation. The changes always result from imbalance between active matrix metalloproteinases (MMPs) and their inhibitors – TIMPs. Abdominal aorta is the most common location for the aneurysm. The risk of developing AAA increases with age. It is more common in men. Its rupture is associated with a high risk of death. The pathogenesis of AAA is complex and still not fully understood. In pathophysiological processes, aortic wall degeneration and atherosclerosis dominate. The factors involved in the pathogenesis of AAA and TAA are not quite the same. Important factors involved in the formation of AAA and increasing the risk of its rupture are MMPs. Also, polymorphisms of numerous genes have been associated with the risk of developing AAA. The two groups of factors related to AAA formation and development are presented and discussed in this work.

Keywords: abdominal aortic aneurysm pathogenesismetalloproteinasesrisk factors

Article available in PDF format

View PDF Download PDF file

References

  1. Davis FM, Rateri DL, Daugherty A. Abdominal aortic aneurysm: novel mechanisms and therapies. Curr Opin Cardiol. 2015; 30(6): 566–573.
    CrossRefPubMed
  2. Mao SS, Ahmadi N, Shah B, et al. Normal thoracic aorta diameter on cardiac computed tomography in healthy asymptomatic adults: impact of age and gender. Acad Radiol. 2008; 15(7): 827–834.
    CrossRefPubMed
  3. Noszczyk W. Rys historyczny leczenia chorób naczyń. In: Noszczyk W. ed. Chirurgia tętnic i żył obwodowych. PZWL, Warszawa 2007: 3–19.
  4. Dubost C. The first successful resection of an aneurysm of the abdominal aorta followed by re-establishment of continuity using a preserved human arterial graft. Ann Vasc Surg. 1986; 1(1): 147–149.
    CrossRefPubMed
  5. DEBAKEY ME, HENLY WS, COOLEY DA, et al. SURGICAL MANAGEMENT OF DISSECTING ANEURYSMS OF THE AORTA. J Thorac Cardiovasc Surg. 1965; 49: 130–149.
    PubMed
  6. Volodos' NL, Shekhanin VE, Karpovich IP, et al. [A self-fixing synthetic blood vessel endoprosthesis]. Vestn Khir Im I I Grek. 1986; 137(11): 123–125.
    PubMed
  7. Sakalihasan N, Michel JB, Katsargyris A, et al. MR imaging of iron phagocytosis in intraluminal thrombi of abdominal aortic aneurysms in humans. Radiology. 2010; 254(3): 973–981.
    CrossRefPubMed
  8. Hirsch A, Haskal Z, Hertzer N, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation. 2006; 113(11): 463–\654.
    CrossRef
  9. Jamrozik K, Norman PE, Spencer CA, et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust. 2000; 173(7): 345–350.
    CrossRefPubMed
  10. Nordon IM, Hinchliffe RJ, Malkawi AH, et al. Modern treatment of juxtarenal abdominal aortic aneurysms with fenestrated endografting and open repair--a systematic review. Eur J Vasc Endovasc Surg. 2009; 38(1): 35–41.
    CrossRefPubMed
  11. Fillinger M. Abdominal Aortic Aneurysms. Rutherford's Vascular Surgery. 2010: 1928–1948.
    CrossRef
  12. Studzińska D, Rudel B, Lewandowski K, et al. The prevalence of renal vascular and anatomical anomalies in patients with abdominal aortic aneurysm. Chir Pol. 2018; 20: 31–34.
  13. Correction. Circulation. 2012; 125(8).
    CrossRef
  14. Khan S, Verma V, Verma S, et al. Assessing the potential risk of rupture of abdominal aortic aneurysms. Clin Radiol. 2015; 70(1): 11–20.
    CrossRefPubMed
  15. Ruptured Abdominal Aortic Aneurysm. Definitions. 2020.
    CrossRef
  16. Keisler B, Carter C. Abdominal aortic aneurysm. Am Fam Physician. 2015; 91(8): 538–543.
    PubMed
  17. Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010; 52(3): 539–548.
    CrossRefPubMed
  18. Altobelli E, Rapacchietta L, Profeta VF, et al. Risk Factors for Abdominal Aortic Aneurysm in Population-Based Studies: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2018; 15(12).
    CrossRefPubMed
  19. Stackelberg O, Wolk A, Eliasson K, et al. Lifestyle and Risk of Screening-Detected Abdominal Aortic Aneurysm in Men. J Am Heart Assoc. 2017; 6(5).
    CrossRefPubMed
  20. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol. 2000; 151(6): 575–583.
    CrossRefPubMed
  21. Cornuz J, Sidoti Pinto C, Tevaearai H, et al. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health. 2004; 14(4): 343–349.
    CrossRefPubMed
  22. Tromp G, Kuivaniemi H, Hinterseher I, et al. Novel genetic mechanisms for aortic aneurysms. Curr Atheroscler Rep. 2010; 12(4): 259–266.
    CrossRefPubMed
  23. Ruddy JM, Jones JA, Spinale FG, et al. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008; 136(5): 1123–1130.
    CrossRefPubMed
  24. Sawicki W, Malejczyk J. Histologia. PZWL, Warszawa 2012: 326–327.
  25. Wolinsky H. Comparison of medial growth of human thoracic and abdominal aortas. Circ Res. 1970; 27(4): 531–538.
    CrossRefPubMed
  26. Wytyczne ESC. dotyczące rozpoznawania i leczenia chorób aorty w 2014 roku. Kardiol Pol. 2014; 72: 1169–1252.
  27. Fanjul-Fernández M, Folgueras AR, Cabrera S, et al. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010; 1803(1): 3–19.
    CrossRefPubMed
  28. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004; 20(4): 419–432.
    CrossRefPubMed
  29. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007; 8(3): 221–233.
    CrossRefPubMed
  30. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015; 44-46: 247–254.
    CrossRefPubMed
  31. Quintana RA, Taylor WR. Cellular Mechanisms of Aortic Aneurysm Formation. Circ Res. 2019; 124(4): 607–618.
    CrossRefPubMed
  32. Saracini C, Bolli P, Sticchi E, et al. Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm. J Vasc Surg. 2012; 55(1): 171–179.e2.
    CrossRefPubMed
  33. Newman KM, Jean-Claude J, Li H, et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 1994; 20(5): 814–820.
    CrossRefPubMed
  34. Courtois A, Nusgens BV, Hustinx R, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med. 2013; 54(10): 1740–1747.
    CrossRefPubMed
  35. Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science. 1999; 284(5420): 1667–1670.
    CrossRefPubMed
  36. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8): 827–839.
    CrossRefPubMed
  37. Carrell TWG, Burnand KG, Wells GMA, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation. 2002; 105(4): 477–482.
    CrossRefPubMed
  38. Theruvath TP, Jones JA, Ikonomidis JS. Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg. 2012; 27(1): 81–90.
    CrossRefPubMed
  39. Deguara J, Burnand KG, Berg J, et al. An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Hum Mol Genet. 2007; 16(24): 3002–3007.
    CrossRefPubMed
  40. Morris DR, Biros E, Cronin O, et al. The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis. Heart. 2014; 100(4): 295–302.
    CrossRefPubMed
  41. Ramella M, Boccafoschi F, Bellofatto K, et al. Endothelial MMP-9 drives the inflammatory response in abdominal aortic aneurysm (AAA). Am J Transl Res. 2017; 9(12): 5485–5495.
    PubMed
  42. Kunecki M, Danilewicz M, Nawrocka-Kunecka A. Usefulness of serum VEGF concentration measurement to estimate aortic aneurysm risk of rupture. Acta Angiol. 2006; 12: 7–15.
  43. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10): 737–744.
    CrossRefPubMed
  44. Aortic Aneurysm and Aortic Dissection. 2020.
    CrossRef
  45. Fic P, Zakrocka I, Kurzepa J, et al. [Matrix metalloproteinases and atherosclerosis]. Postepy Hig Med Dosw (Online). 2011; 65: 16–27.
    CrossRefPubMed
  46. Trojanek BJ. Rola metaloproteinaz macierzy zewnątrzkomórkowej i tkankowych inhibitorów metaloproteinaz w nadciśnieniu tętniczym. Patogeneza nadciśnienia a problem otyłości. Post Bioch. 2015; 61: 356–58.
  47. Johnson JL. Metalloproteinases in atherosclerosis. Eur J Pharmacol. 2017; 816: 93–106.
    CrossRefPubMed
  48. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000; 105(11): 1641–1649.
    CrossRefPubMed
  49. Mao D, Lee JK, VanVickle SJ, et al. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun. 1999; 261(3): 904–910.
    CrossRefPubMed
  50. Tromp G, Gatalica Z, Skunca M, et al. Elevated expression of matrix metalloproteinase-13 in abdominal aortic aneurysms. Ann Vasc Surg. 2004; 18(4): 414–420.
    CrossRefPubMed
  51. Nollendorfs A, Greiner TC, Nagase H, et al. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J Vasc Surg. 2001; 34(2): 316–322.
    CrossRefPubMed
  52. Xiong W, Knispel R, MacTaggart J, et al. Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J Biol Chem. 2009; 284(3): 1765–1771.
    CrossRefPubMed
  53. Clifton MA. Familial abdominal aortic aneurysms. Br J Surg. 1977; 64(11): 765–766.
    CrossRefPubMed
  54. Bradley DT, Badger SA, McFarland M, et al. Abdominal Aortic Aneurysm Genetic Associations: Mostly False? A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2016; 51(1): 64–75.
    CrossRefPubMed
  55. https://www.snpedia.com/index.php/Rs10757278 (1.12.2019).
  56. Bayoglu B, Cakmak HA, Yuksel H, et al. Chromosome 9p21 rs10757278 polymorphism is associated with the risk of metabolic syndrome. Mol Cell Biochem. 2013; 379(1-2): 77–85.
    CrossRefPubMed
  57. Goettsch C, Kjolby M, Aikawa E. Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases. Arterioscler Thromb Vasc Biol. 2018; 38(1): 19–25.
    CrossRefPubMed
  58. Bown MJ, Jones GT, Harrison SC, et al. CARDIoGRAM Consortium, Global BPgen Consortium, DIAGRAM Consortium, VRCNZ Consortium. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011; 89(5): 619–627.
    CrossRefPubMed
  59. Galora S, Saracini C, Pratesi G, et al. Association of rs1466535 LRP1 but not rs3019885 SLC30A8 and rs6674171 TDRD10 gene polymorphisms with abdominal aortic aneurysm in Italian patients. J Vasc Surg. 2015; 61(3): 787–792.
    CrossRefPubMed
  60. Giusti B, Galora S, Saracini C, et al. Role of rs1466535 low density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism in carotid artery disease. Atherosclerosis. 2014; 237(1): 135–137.
    CrossRefPubMed
  61. https://www.snpedia.com/index.php/Rs5186 (1.12.2019).
  62. https://ghr.nlm.nih.gov/gene/AGTR1 (1.12.2019).
  63. https://www.snpedia.com/index.php/Rs4646994 (1.12.2019).
  64. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417(6891): 822–828.
    CrossRefPubMed
  65. https://www.snpedia.com/index.php/Rs964184 (1.12.2019).

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Acta Angiologica

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice